Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:KYMR 8 December 2025 - 4 January 2026

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics shares fell 6.5% to $72.76 on Friday, marking a seventh straight daily loss and leaving the stock down 29% from its early December peak. About 854,000 shares traded as investors shifted focus to 2026 trial milestones and funding. CEO Nello Mainolfi sold 30,000 shares in a pre-arranged plan on Dec. 31. The company raised $602 million in a December stock offering at $86 per share.
4 January 2026
·
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··

Stock Market Today

  • US Stock Futures Dip Over 0.5% Amid Renewed Middle East Tensions
    April 9, 2026, 10:02 AM EDT. US stock futures for the Dow Jones, S&P 500, and Nasdaq fell between 0.3% and 0.6% on Thursday, reflecting concerns over the fragile ceasefire in the Middle East. Iran accused Israel of violating ceasefire terms by attacking Lebanon, leading Tehran to close the key Strait of Hormuz again. This strategic waterway handles nearly 20% of global oil shipments, raising fears of supply disruption and economic slowdown. President Trump affirmed US troop presence in the region, warning of strong military action if Iran fails to comply with demands. Crude oil prices responded, with Brent crude rising 4% to $97.03 a barrel and US crude up 4.2% at $98.42. The market is bracing for potential volatility as peace talks in Islamabad approach.

Latest article

Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

9 April 2026
Nokia was named a Leader and Outperformer in GigaOm’s 2026 Radar for data center switching for the fifth year in a row, competing with Cisco, Arista, and HPE Juniper. Shares fell 1.05% in Helsinki ahead of Thursday’s annual meeting, where board changes and a dividend of up to 14 euro cents per share will be considered.
American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

9 April 2026
The FAA proposed a $255,000 civil penalty against American Airlines, alleging the carrier allowed 12 flight attendants who tested positive for drugs or alcohol to return to safety-sensitive duties before completing required follow-up tests. The alleged violations occurred from May 2019 to December 2023. American has 30 days to respond. The airline said it is reviewing the notice.
Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

9 April 2026
Blackstone and TPG closed their $17.3 billion acquisition of Hologic on April 7, with José Almeida replacing Steve MacMillan as CEO. Hologic shares were suspended before trading that day and will be removed from the S&P 500 before Thursday’s open. Former shareholders will receive $76 per share in cash plus a contingent value right worth up to $3 more if revenue targets are met.
When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
Go toTop